These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 18676886)

  • 1. Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers.
    Jhee SS; Yen M; Ereshefsky L; Leibowitz M; Schulte M; Kaeser B; Boak L; Patel A; Hoffmann G; Prinssen EP; Rayner CR
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3687-93. PubMed ID: 18676886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absence of central nervous system and hypothermic effects after single oral administration of high doses of oseltamivir in the rat.
    Freichel C; Breidenbach A; Hoffmann G; Körner A; Gatti S; Donner B; Bansod S; Bellot M; Gand L; Weiser T; Singer T; Prinssen EP
    Basic Clin Pharmacol Toxicol; 2012 Jul; 111(1):50-7. PubMed ID: 22309322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review.
    Toovey S; Rayner C; Prinssen E; Chu T; Donner B; Thakrar B; Dutkowski R; Hoffmann G; Breidenbach A; Lindemann L; Carey E; Boak L; Gieschke R; Sacks S; Solsky J; Small I; Reddy D
    Drug Saf; 2008; 31(12):1097-114. PubMed ID: 19026027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of high-dose oseltamivir in healthy volunteers.
    Wattanagoon Y; Stepniewska K; Lindegårdh N; Pukrittayakamee S; Silachamroon U; Piyaphanee W; Singtoroj T; Hanpithakpong W; Davies G; Tarning J; Pongtavornpinyo W; Fukuda C; Singhasivanon P; Day NP; White NJ
    Antimicrob Agents Chemother; 2009 Mar; 53(3):945-52. PubMed ID: 19104028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Similarity in pharmacokinetics of oseltamivir and oseltamivir carboxylate in Japanese and Caucasian subjects.
    Schentag JJ; Hill G; Chu T; Rayner CR
    J Clin Pharmacol; 2007 Jun; 47(6):689-96. PubMed ID: 17456583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oseltamivir, an influenza neuraminidase inhibitor drug, does not affect the steady-state pharmacokinetic characteristics of cyclosporine, mycophenolate, or tacrolimus in adult renal transplant patients.
    Lam H; Jeffery J; Sitar DS; Aoki FY
    Ther Drug Monit; 2011 Dec; 33(6):699-704. PubMed ID: 22105586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies.
    Rayner CR; Bulik CC; Kamal MA; Reynolds DK; Toovey S; Hammel JP; Smith PF; Bhavnani SM; Van Wart SA; Ambrose PG; Forrest A
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3478-87. PubMed ID: 23669386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and safety of intravenous oseltamivir in infants and children in open-label studies.
    Muñoz FM; Anderson EJ; Deville JG; Clinch B; Kamal MA
    Int J Clin Pharmacol Ther; 2015 Jul; 53(7):531-40. PubMed ID: 26042486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuraminidase inhibitors for preventing and treating influenza in adults and children.
    Jefferson T; Jones MA; Doshi P; Del Mar CB; Hama R; Thompson MJ; Spencer EA; Onakpoya I; Mahtani KR; Nunan D; Howick J; Heneghan CJ
    Cochrane Database Syst Rev; 2014 Apr; 2014(4):CD008965. PubMed ID: 24718923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection.
    Sugaya N; Ohashi Y
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2575-82. PubMed ID: 20368393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Drug-Drug Interaction Potential between Baloxavir Marboxil and Oseltamivir in Healthy Subjects.
    Kawaguchi N; Koshimichi H; Ishibashi T; Wajima T
    Clin Drug Investig; 2018 Nov; 38(11):1053-1060. PubMed ID: 30203386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High levels and safety of oseltamivir carboxylate plasma concentrations after nasogastric administration in critically ill children in a pediatric intensive care unit.
    Giraud C; Manceau S; Oualha M; Chappuy H; Mogenet A; Duchêne P; Ducrocq S; Hubert P; Treluyer JM
    Antimicrob Agents Chemother; 2011 Jan; 55(1):433-5. PubMed ID: 20937783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of new oral dosing regimens for the neuraminidase inhibitor oseltamivir in patients with moderate and severe renal impairment.
    Kamal MA; Brennan BJ; Subramoney V; Lien YT; Morcos PN; Frey N; Rayner CR
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):326-36. PubMed ID: 27137141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis.
    Jefferson T; Jones M; Doshi P; Del Mar C
    BMJ; 2009 Dec; 339():b5106. PubMed ID: 19995812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, tolerability, and pharmacokinetics of intravenous oseltamivir: single- and multiple-dose phase I studies with healthy volunteers.
    Brennan BJ; Davies B; Cirrincione-Dall G; Morcos PN; Beryozkina A; Chappey C; Aceves Baldó P; Lennon-Chrimes S; Rayner CR
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4729-37. PubMed ID: 22733065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids.
    Snell P; Oo C; Dorr A; Barrett J
    Br J Clin Pharmacol; 2002 Oct; 54(4):372-7. PubMed ID: 12392584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuraminidase inhibitors for preventing and treating influenza in healthy adults.
    Jefferson T; Jones M; Doshi P; Del Mar C; Dooley L; Foxlee R
    Cochrane Database Syst Rev; 2010 Feb; 2011(2):CD001265. PubMed ID: 20166059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and tolerability of oseltamivir combined with probenecid.
    Holodniy M; Penzak SR; Straight TM; Davey RT; Lee KK; Goetz MB; Raisch DW; Cunningham F; Lin ET; Olivo N; Deyton LR
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3013-21. PubMed ID: 18559644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children.
    Oo C; Barrett J; Hill G; Mann J; Dorr A; Dutkowski R; Ward P
    Paediatr Drugs; 2001; 3(3):229-36. PubMed ID: 11310719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants.
    Parrott N; Davies B; Hoffmann G; Koerner A; Lave T; Prinssen E; Theogaraj E; Singer T
    Clin Pharmacokinet; 2011 Sep; 50(9):613-23. PubMed ID: 21827216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.